Immunotherapy of glioblastoma multiforme

Keith L Knutson, Lupe Salazar, Kathy Schiffman, Mary L. Disis

Research output: Contribution to journalArticle

Abstract

Glioblastoma multiforme is immunogenic and several glioblastoma multiforme-related antigens have now been identified. In addition, the immunologic characteristics of the tumor microenvironment that may affect tumor growth are becoming increasingly understood. The type of immune-based approach selected to treat glioblastoma multiforme will depend on the tumor burden. For minimal disease states, active vaccination may be useful for generating adequate protection from relapse. However, for more advanced stage disease states, more rigorous strategies may need to be applied, such as adoptive T-cell therapy, antibody therapy or a combination of different techniques. The immunosuppressive environment observed during advanced malignancy may need to be reversed for improved efficacy of immune-based therapies.

Original languageEnglish (US)
Pages (from-to)511-523
Number of pages13
JournalExpert Review of Neurotherapeutics
Volume3
Issue number4
StatePublished - Jul 2003
Externally publishedYes

Fingerprint

Glioblastoma
Immunotherapy
Tumor Microenvironment
Immunosuppressive Agents
Cell- and Tissue-Based Therapy
Tumor Burden
Neoplasms
Vaccination
T-Lymphocytes
Antigens
Recurrence
Antibodies
Therapeutics
Growth

Keywords

  • Adoptive T-cell therapy
  • Antigens
  • Cancer vaccines
  • Cytokines
  • Glioblastoma multiforme
  • T-lymphocytes
  • Tumor immunology

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Knutson, K. L., Salazar, L., Schiffman, K., & Disis, M. L. (2003). Immunotherapy of glioblastoma multiforme. Expert Review of Neurotherapeutics, 3(4), 511-523.

Immunotherapy of glioblastoma multiforme. / Knutson, Keith L; Salazar, Lupe; Schiffman, Kathy; Disis, Mary L.

In: Expert Review of Neurotherapeutics, Vol. 3, No. 4, 07.2003, p. 511-523.

Research output: Contribution to journalArticle

Knutson, KL, Salazar, L, Schiffman, K & Disis, ML 2003, 'Immunotherapy of glioblastoma multiforme', Expert Review of Neurotherapeutics, vol. 3, no. 4, pp. 511-523.
Knutson KL, Salazar L, Schiffman K, Disis ML. Immunotherapy of glioblastoma multiforme. Expert Review of Neurotherapeutics. 2003 Jul;3(4):511-523.
Knutson, Keith L ; Salazar, Lupe ; Schiffman, Kathy ; Disis, Mary L. / Immunotherapy of glioblastoma multiforme. In: Expert Review of Neurotherapeutics. 2003 ; Vol. 3, No. 4. pp. 511-523.
@article{04d0fe9095ff481e98c1497955a72cb8,
title = "Immunotherapy of glioblastoma multiforme",
abstract = "Glioblastoma multiforme is immunogenic and several glioblastoma multiforme-related antigens have now been identified. In addition, the immunologic characteristics of the tumor microenvironment that may affect tumor growth are becoming increasingly understood. The type of immune-based approach selected to treat glioblastoma multiforme will depend on the tumor burden. For minimal disease states, active vaccination may be useful for generating adequate protection from relapse. However, for more advanced stage disease states, more rigorous strategies may need to be applied, such as adoptive T-cell therapy, antibody therapy or a combination of different techniques. The immunosuppressive environment observed during advanced malignancy may need to be reversed for improved efficacy of immune-based therapies.",
keywords = "Adoptive T-cell therapy, Antigens, Cancer vaccines, Cytokines, Glioblastoma multiforme, T-lymphocytes, Tumor immunology",
author = "Knutson, {Keith L} and Lupe Salazar and Kathy Schiffman and Disis, {Mary L.}",
year = "2003",
month = "7",
language = "English (US)",
volume = "3",
pages = "511--523",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Immunotherapy of glioblastoma multiforme

AU - Knutson, Keith L

AU - Salazar, Lupe

AU - Schiffman, Kathy

AU - Disis, Mary L.

PY - 2003/7

Y1 - 2003/7

N2 - Glioblastoma multiforme is immunogenic and several glioblastoma multiforme-related antigens have now been identified. In addition, the immunologic characteristics of the tumor microenvironment that may affect tumor growth are becoming increasingly understood. The type of immune-based approach selected to treat glioblastoma multiforme will depend on the tumor burden. For minimal disease states, active vaccination may be useful for generating adequate protection from relapse. However, for more advanced stage disease states, more rigorous strategies may need to be applied, such as adoptive T-cell therapy, antibody therapy or a combination of different techniques. The immunosuppressive environment observed during advanced malignancy may need to be reversed for improved efficacy of immune-based therapies.

AB - Glioblastoma multiforme is immunogenic and several glioblastoma multiforme-related antigens have now been identified. In addition, the immunologic characteristics of the tumor microenvironment that may affect tumor growth are becoming increasingly understood. The type of immune-based approach selected to treat glioblastoma multiforme will depend on the tumor burden. For minimal disease states, active vaccination may be useful for generating adequate protection from relapse. However, for more advanced stage disease states, more rigorous strategies may need to be applied, such as adoptive T-cell therapy, antibody therapy or a combination of different techniques. The immunosuppressive environment observed during advanced malignancy may need to be reversed for improved efficacy of immune-based therapies.

KW - Adoptive T-cell therapy

KW - Antigens

KW - Cancer vaccines

KW - Cytokines

KW - Glioblastoma multiforme

KW - T-lymphocytes

KW - Tumor immunology

UR - http://www.scopus.com/inward/record.url?scp=0038376938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038376938&partnerID=8YFLogxK

M3 - Article

C2 - 19810935

AN - SCOPUS:0038376938

VL - 3

SP - 511

EP - 523

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 4

ER -